» Articles » PMID: 3861106

Immunobiology of the Dunning R-3327 Rat Prostate Adenocarcinoma Sublines: Plasma and Tumor Effusion Prostaglandins

Overview
Date 1985 Jul 1
PMID 3861106
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Enhanced production of prostaglandins (PGs) by experimentally-induced and naturally occurring tumors and their effect on tumor growth and immunosurveillance have been noted. Directed toward further evaluation of the relationship between prostatic tumor growth and its milieu, i.e., microenvironment, we investigated the possible correlation between levels of PGs, tumor size, and metastatic potential. For this purpose, the levels of PGE2 and PGF2 alpha in plasma and tumor effusions of three tumor sublines of the Dunning R-3327 rat prostate adenocarcinoma were measured: R-3327H, well-differentiated, slow-growing, and poorly metastatic; R-3327G, poorly differentiated, fast-growing, and poorly metastatic; and R-3327 Mat LyLu, anaplastic, fast-growing, and highly metastatic. The level of PGF2 alpha was highly variable with no significant differences being noted between the tumor sublines. The mean values of PGF2 alpha were, however, higher, although not significantly so, in the smaller tumors within each of the sublines. The levels of PGE2 were significantly higher in Mat LyLu effusions than those from the nonmetastasizing R-3327G and H sublines. Evaluation and comparison of the relationship between tumor burden, i.e., size versus levels of PGE2 and PGF2 alpha showed no significant differences. A vasodilator and regulator of immunological responsiveness, PGE2, may function as a modulator of tumor metastases. In consonance with studies by others elevated levels of PGE2 may possibly serve as a prognostic marker for the high metastatic potential of neoplastic cells.

Citing Articles

The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer.

Hryniewicz-Jankowska A, Augoff K, Sikorski A Exp Biol Med (Maywood). 2019; 244(13):1053-1061.

PMID: 31573840 PMC: 6775568. DOI: 10.1177/1535370219870771.


ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.

Wu X, Deng F, Li Y, Daniels G, Du X, Ren Q Oncotarget. 2015; 6(42):44849-63.

PMID: 26636648 PMC: 4792596. DOI: 10.18632/oncotarget.6438.


Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy.

Zaorsky N, Buyyounouski M, Li T, Horwitz E Int J Radiat Oncol Biol Phys. 2012; 84(1):e13-7.

PMID: 22652109 PMC: 3423546. DOI: 10.1016/j.ijrobp.2012.02.050.


Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.

Kobayashi N, Barnard R, Henning S, Elashoff D, Reddy S, Cohen P Clin Cancer Res. 2006; 12(15):4662-70.

PMID: 16899616 PMC: 3410648. DOI: 10.1158/1078-0432.CCR-06-0459.


Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.

Jiang J, Neubauer B, Graff J, Chedid M, Thomas J, Roehm N Am J Pathol. 2002; 160(2):667-71.

PMID: 11839587 PMC: 1850653. DOI: 10.1016/S0002-9440(10)64886-9.